Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
Recruiting · NCT05062837 · Registry updated 2026-10-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05062837 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Guangxi Medical University | 14 |
| Jiangsu HengRui Medicine Co., Ltd. | 132 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangxi Medical University Cancer Hospital | Nanning | China | 4 |